Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive, functional, behavioral, global changes and adverse effects in patients with mild, moderate and severe Alzheimer’s disease (AD), we screened the literature published before September 2017 in the Pubmed, Embase, C...
Main Authors: | Dan-Dan Li, Ya-Hong Zhang, Wei Zhang, Pu Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2019.00472/full |
Similar Items
-
The Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
by: Farhad Iranmanesh, et al.
Published: (2020-03-01) -
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model
by: M Bond, et al.
Published: (2012-04-01) -
Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review
by: Ramin Abdi Dezfouli, et al.
Published: (2024-02-01) -
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
by: Débora Nunes, et al.
Published: (2022-10-01) -
What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink
by: Venexia M. Walker, et al.
Published: (2018-05-01)